Farxiga (dapaglifozin) has been approved by the U.S. Food and Drug Administration to treat adults with type 2 diabetes, the agency said Wednesday in a news release. The drug, to be used for blood sugar control along with proper diet and ...
Tags: Farxiga, Type 2 Diabetes, Medicine News
Children who are critically ill after having heart surgery do not benefit from having their blood sugar levels aggressively controlled, but some kids with other life-threatening conditions might, a new study suggests. Experts said the ...
Tags: Blood Sugar, Blood Sugar Control, Ill Kids
Here are some of the latest health and medical news developments, compiled by the editors of HealthDay: Officials Confirm First North American Death From H5N1 Bird Flu The first death in North America from H5N1 bird flu has been ...
Tags: Health Highlights, Health
Typical, nonsurgical treatment of gum disease in people with type 2 diabetes will not improve their blood-sugar control, a new study suggests. There's long been a connection between gum disease and wider health issues, and experts say a ...
Tags: gum disease, type 2 diabetes, blood-sugar control, diabetes
Daily exercise lessens many of the harmful physiological effects of short-term overeating and inactivity, British researchers say. "This new research shows that the picture is more sophisticated than 'energy' alone: exercise has positive ...
A recent study on over 1,900 French men and women analyzed diet, sun exposure, physical activity, age, and geographic location. The study followed participants for over two and a half years and found that those with the lowest levels of ...
The US FDA has approved Novo Nordisk Victoza (liraglutide [rDNA] injection) label to include data showing superior blood sugar control and weight reduction when compared to Januvia (sitagliptin). Label update also includes approval of ...
Tags: Label update, type 2 diabetes, Victoza
The US Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) of Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company for Tradjenta (linagliptin) tablets for use as add-on therapy to insulin. ...
Tags: FDA, sNDA, pharmaceutical product, clinical development